Needham & Company LLC reaffirmed their buy rating on shares of G1 Therapeutics (NASDAQ:GTHX) in a report published on Wednesday morning, AnalystRatings.com reports. The brokerage currently has a $74.00 price objective on the stock.

GTHX has been the topic of several other research reports. Zacks Investment Research cut shares of G1 Therapeutics from a buy rating to a hold rating in a report on Friday, June 19th. Wedbush reduced their target price on shares of G1 Therapeutics from $55.00 to $50.00 and set an outperform rating on the stock in a report on Wednesday. BidaskClub raised shares of G1 Therapeutics from a hold rating to a buy rating in a report on Tuesday, June 23rd. ValuEngine cut shares of G1 Therapeutics from a buy rating to a hold rating in a report on Tuesday, March 10th. Finally, Roth Capital assumed coverage on shares of G1 Therapeutics in a report on Friday, June 26th. They issued a buy rating and a $55.00 target price on the stock. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The company has a consensus rating of Buy and a consensus target price of $55.38.

Shares of GTHX opened at $21.54 on Wednesday. The stock has a market capitalization of $812.86 million, a PE ratio of -6.26 and a beta of 2.33. G1 Therapeutics has a 1 year low of $8.80 and a 1 year high of $41.80. The company has a debt-to-equity ratio of 0.04, a quick ratio of 13.20 and a current ratio of 13.20. The company’s 50-day simple moving average is $19.72 and its 200-day simple moving average is $18.69.

G1 Therapeutics (NASDAQ:GTHX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.98) by $0.16. On average, sell-side analysts predict that G1 Therapeutics will post -3.59 earnings per share for the current year.

Institutional investors have recently made changes to their positions in the business. Rocky Mountain Advisers LLC purchased a new position in G1 Therapeutics in the first quarter valued at approximately $25,000. Great West Life Assurance Co. Can purchased a new position in G1 Therapeutics in the fourth quarter valued at approximately $60,000. Advisor Group Holdings Inc. purchased a new position in G1 Therapeutics in the first quarter valued at approximately $41,000. Bank of Montreal Can increased its stake in G1 Therapeutics by 43.7% in the fourth quarter. Bank of Montreal Can now owns 4,264 shares of the company’s stock valued at $113,000 after purchasing an additional 1,296 shares during the last quarter. Finally, Victory Capital Management Inc. increased its stake in G1 Therapeutics by 12.9% in the fourth quarter. Victory Capital Management Inc. now owns 4,646 shares of the company’s stock valued at $123,000 after purchasing an additional 531 shares during the last quarter. Institutional investors own 75.83% of the company’s stock.

About G1 Therapeutics

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase Ib/II clinical trials for patients with extensive-stage small cell lung cancer, as well as Phase II clinical trial for patients with first-/second-/third-line metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase Ib/IIa clinical trials for the treatment of breast cancer and in Phase Ib/II clinical trial for non-small cell lung cancer; and G1T48, an oral selective estrogen receptor degrader, which is in Phase I clinical trial.

Further Reading: Asset Allocation, Balancing Your Investments

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.